The genetic aspect of prevalence and phenotypic expression of pol | 18039
Endocrinology & Metabolic Syndrome

Endocrinology & Metabolic Syndrome
Open Access

ISSN: 2161-1017

+44 1478 350008

The genetic aspect of prevalence and phenotypic expression of polycystic ovarian syndrome

2nd World Congress on Polycystic Ovarian Syndrome

October 05-07, 2016 Orlando, Florida, USA

Dimitrios Jim Belegris

University of Patras Medical School, Greece
IASO, General Maternity and Gynecology Clinic, Greece
Metropolitan Hospital, Greece

Posters & Accepted Abstracts: Endocrinol Metab Syndr

Abstract :

Polycystic ovarian syndrome was first described in 1935, but according to scientific observations it well may be an ancient disorder arising from ancestral gene variants maintained from the Paleolithic period. In modern era, there are several studies that highlight noted differences in the prevalence of the syndrome among ethnic groups. Furthermore, PCOS is a family affair. Male and female relatives and descendants of women with PCOS have been found to have a higher risk for exhibiting the hyper androgenic or metabolic characteristics of the disorder. Recently investigators from Northwestern medicine have managed to identify two new genetic susceptibility regions that appear to be unique to European women with PCOS, as well as one region also present in Chinese women with PCOS. It is remarkable that these new regions contain the gene for FSH and this indicates that the regulation of this pathway plays a significant role in the development of PCOS. Combination of knowledge and scientific observations and further research may enhance our understanding of the etiology of the polycystic ovarian syndrome, and facilitate the management of this condition. Moreover, due to the variation of the phenotypic expression of the syndrome, each patient has to be evaluated individually. A challenge remains the management of sub-fertility in women with PCOS. The Thessaloniki ESHRE/ASRM sponsored PCOS Consensus Workshop group proposed the value of gonadotropin therapy in women with anovulatory PCOS that may lead 70-90% of the occasions in ovulatory cycles and a conception rate of 15-20% respectively.

Biography :